Business
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in Europe
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in Europe.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in Europe\n\nOncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in Europe\n\n\n BATON ROUGE, LA--(Marketwired - March 16, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notice of Allowance for a patent on ProscaVax™, OncBioMune's cancer vaccine in a Phase 1 trial for relapsed prostate cancer patients, from the European Patent Office.The patent, titled \"Composition and Method for Treating Cancer,\" application number 12701292.0, expands the scope of protection of OncBioMune's intellectual property, which now includes 15 patents and patents pending covering approximately 50 countries worldwide for the Company's vaccine and paclitaxel gallium transferrin (PGT) technologies.ProscaVax is a novel protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damaging healthy cells. OncBioMune recently disclosed that while the Phase 1 trial is completed, a Phase 2 trial is expected to be initiated later this year evaluating ProscaVax as a front-line treatment for prostate cancer patients at disease presentation.According to Cancer Research UK, approximately 417,000 men were diagnosed with prostate cancer in Europe in 2012 and more than 92,000 men died from the disease. \"As we explore all developmental avenues globally for ProscaVax, protecting our intellectual property is critical,\" commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. \"Prostate cancer is the most common cancer in Europe for men and the third most common cancer overall. We hope that one day ProscaVax will provide a viable solution in the region to meet this area of great unmet medical need.\"Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.About OncBioMune Pharmaceuticals, Inc.OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system ...